Hot Pursuit     22-Mar-24
Biocon Ltd spurts 1.83%, gains for third straight session
Biocon Ltd is quoting at Rs 253.25, up 1.83% on the day as on 12:49 IST on the NSE. The stock is up 22.34% in last one year as compared to a 29.37% jump in NIFTY and a 59.35% jump in the Nifty Pharma index.

Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 253.25, up 1.83% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.36% on the day, quoting at 22091.6. The Sensex is at 72819.71, up 0.25%. Biocon Ltd has slipped around 7.25% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.44% in last one month and is currently quoting at 18582.6, up 1.03% on the day. The volume in the stock stood at 34.89 lakh shares today, compared to the daily average of 60.4 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 255.75, up 1.81% on the day. Biocon Ltd is up 22.34% in last one year as compared to a 29.37% jump in NIFTY and a 59.35% jump in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 23.

Previous News
  Stock Alert: Force Motors, Biocon, Adani Wilmar, JSW Energy, GE Vernova, ONGC,
 ( Market Commentary - Stock Alert 05-Mar-25   08:36 )
  Nifty trades near 23,550 mark; realty shares rally for 5th day
 ( Market Commentary - Mid-Session 24-Mar-25   10:36 )
  Biocon Ltd eases for fifth straight session
 ( Hot Pursuit - 12-Jul-24   13:36 )
  Biocon Ltd down for fifth straight session
 ( Hot Pursuit - 13-Dec-24   13:35 )
  Barometers pares all gains ; realty shares decline
 ( Market Commentary - Mid-Session 24-May-24   10:36 )
  Biocon to convene board meeting
 ( Corporate News - 02-Apr-25   10:19 )
  Biocon
 ( Results - Analysis 01-Feb-25   16:10 )
  Biocon Ltd soars 3.74%, rises for third straight session
 ( Hot Pursuit - 02-Jan-24   13:05 )
  Biocon arm receives approval for Tacrolimus capsules in China
 ( Hot Pursuit - 03-Jan-25   11:35 )
  Biocon, Zentiva get approval for diabetes tratement drug Liraglutide for EU region
 ( Hot Pursuit - 24-Dec-24   09:37 )
  Biocon features in S&P's Sustainability Yearbook 2024
 ( Corporate News - 20-Feb-24   12:28 )
Other Stories
  IndusInd Bank denies forensic audit by EY, clarifies ongoing internal review
  22-Apr-25   17:41
  Tata Comm records multi-fold jump in Q4 PAT; recommends final dividend of Rs 25/sh
  22-Apr-25   17:35
  AU SFB Q4 PAT climbs 36% YoY to Rs 504 cr
  22-Apr-25   17:18
  Jindal Stainless gains after commissioning Odisha’s largest captive solar energy plant
  22-Apr-25   15:26
  RateGain Travel rallies after renewing partnership with Tunisair
  22-Apr-25   15:16
  REC appoints Jitendra Srivastava as chairman & MD
  22-Apr-25   15:05
  Cholamandalam Investment & Finance Company Ltd leads losers in 'A' group
  22-Apr-25   15:00
  NACL Industries jumps 111% in fifteen days
  22-Apr-25   14:58
  Parshva Enterprises Ltd leads losers in 'B' group
  22-Apr-25   14:45
  Indo Amines edges higher after launching new product aliphatic amines category
  22-Apr-25   14:42
Back Top